The Motley Fool·22h ago
Moderna Stock Is Soaring. Is It Too Late to Buy?Moderna is no longer just a COVID-19 vaccine company. A growing pipeline could fuel long-term revenue growth.
Moderna, Inc.(MRNA)Earnings, Financials & Key Ratios
MRNA•NASDAQ
$79.77
Price updated Jul 7, 2026
AboutModerna, Inc., a biotechnology company, discovers, develops, and commercializes messenger RNA therapeutics and vaccines for the treatment of infectious diseases, immuno-oncology, rare diseases, cardiovascular diseases, and auto-immune diseases in the United States, Europe, and internationally. Its respiratory vaccines include COVID-19, flu, respiratory syncytial virus, Endemic HCoV, and hMPV+PIV3 vaccines; latent vaccines comprise cytomegalovirus, epstein-barr virus, human immunodeficiency virus, herpes simplex virus, and varicella-zoster virus vaccines; and public health vaccines consists of Zika and Nipah vaccines. The company also offers systemic secreted and cell surface therapeutics; cancer vaccines, such as personalized cancer, KRAS, and checkpoint vaccines; intratumoral immuno-oncology products; localized regenerative, systemic intracellular, and inhaled pulmonary therapeutics. It has strategic alliances with AstraZeneca PLC; Merck & Co., Inc.; Vertex Pharmaceuticals Incorporated; Vertex Pharmaceuticals (Europe) Limited; Carisma Therapeutics, Inc.; Metagenomi, Inc.; the Defense Advanced Research Projects Agency; Biomedical Advanced Research and Development Authority; Institute for Life Changing Medicines; and The Bill & Melinda Gates Foundation, as well as a collaboration and license agreement with Chiesi Farmaceutici S.P.A. The company was formerly known as Moderna Therapeutics, Inc. and changed its name to Moderna, Inc. in August 2018. Moderna, Inc. was founded in 2010 and is headquartered in Cambridge, Massachusetts.Show more
- Revenue$1.94B-39.2%
- EBITDA-$2.86B+23.9%
- Net Income-$2.82B+20.8%
- EPS (Diluted)-7.26+21.7%
- Gross Margin55.35%+2.1%
- EBITDA Margin-147.07%-25.3%
- Operating Margin-158.13%-28.2%
- Net Margin-145.16%-30.4%
- ROE-28.87%-0.3%
MRNA Price & Volume
Moderna, Inc. (MRNA) stock price & volume — 10-year historical chart
Loading chart...
Moderna Faces Severe Post-Pandemic Revenue Contraction
Investment Thesis • Updated 2026Q1
VerdictNegative: The company's inability to generate positive operating income
Growth:Contracting
Profitability:Negative
Financial:Strained
Cash Flow:Burning
Primary Risk:Excessive Fixed Cost Base
Key Thesis Takeaways
- Moderna is currently navigating a difficult transition from pandemic-era government procurement to a volatile, seasonal commercial market, resulting in significant margin compression and persistent operating losses.
- While the company maintains a substantial R&D pipeline, the current burn rate, evidenced by a $1.3 billion net loss in 2026Q1, raises concerns regarding the sustainability of its capital allocation strategy.
- Investors should monitor the company's ability to stabilize its manufacturing footprint and achieve commercial success for its non-COVID pipeline to offset the ongoing erosion of its cash reserves.
Verdict Logic
highlighted by a -3.6% operating margin in 2026Q1, suggests that the current cost structure remains unsustainable without a significant rebound in product demand.
MRNA Growth Metrics
Moderna, Inc. (MRNA) revenue, earnings & EPS growth — 3, 5 & 10-year CAGR
Revenue CAGR
10 Years-
5 Years19.33%
3 Years-53.13%
TTM-29.12%
Profit CAGR
10 Years-
5 Years-
3 Years-
TTM4.86%
EPS CAGR
10 Years-
5 Years-
3 Years-
TTM6.62%
Return on Capital
10 Years-3.18%
5 Years23.14%
3 Years-26.59%
Last Year-27.59%
MRNA Recent Earnings
Moderna, Inc. (MRNA) EPS & revenue vs analyst estimates — last 4 quarters
●Beat EPS 12/12 qtrs (100%)●Beat Revenue 10/12 qtrs (83%)
Q2 2026Latest
May 1, 2026Metric
Actual
Est
EPS
$3.40+23.6%
$4.45
Rev
$389M+64.6%
$236M
Q1 2026
Feb 13, 2026Metric
Actual
Est
EPS
$2.11+16.9%
$2.54
Rev
$678M+6.7%
$635M
Q4 2025
Nov 6, 2025Metric
Actual
Est
EPS
$0.51+72.7%
$1.87
Rev
$1.0B+10.3%
$921M
Q3 2025
Aug 1, 2025Metric
Actual
Est
EPS
$2.13+28.8%
$2.99
Rev
$142M-84.1%
$893M
| Quarter | Date | EPS (Act vs Est) | Revenue (Act vs Est) |
|---|---|---|---|
| Q2 2026Latest | May 1, 2026 | $3.40vs $4.45+23.6% | $389Mvs $236M+64.6% |
| Q1 2026 | Feb 13, 2026 | $2.11vs $2.54+16.9% | $678Mvs $635M+6.7% |
| Q4 2025 | Nov 6, 2025 | $0.51vs $1.87+72.7% | $1.0Bvs $921M+10.3% |
| Q3 2025 | Aug 1, 2025 | $2.13vs $2.99+28.8% | $142Mvs $893M-84.1% |
Based on last 12 quarters of dataView full earnings history →
Latest MRNA News
Recent stock market news and headlines for Moderna, Inc. (MRNA)
Zacks Investment Research·1 day ago
Moderna (MRNA) Outpaces Stock Market Gains: What You Should KnowModerna (MRNA) closed at $81.76 in the latest trading session, marking a +2.51% move from the prior day.
The Motley Fool·1 day ago
These 3 Stocks Trounced the S&P 500 in the First Half of 2026 -- and Wall Street Thinks 1 of Them Could Soar Even MoreEach of these biotech players has reached an important turning point. Recent drug approvals could supercharge the performance of one in particular.
InvestorPlace·2 days ago
2 More Stocks to Buy for the AI ConvergenceTom Yeung here with your Sunday Digest . In the days following its IPO, Space Exploration Technologies Corp. ( SPCX ) surged 25%, rewarding early investors and turning its owner, Elon Musk, into a trillionaire.
The Motley Fool·4 days ago
Moderna Is Up More Than 70% in a Month After a 9-0 FDA Vote. Wall Street's Average Price Target Says It Should Fall 44%.An FDA advisory panel voted 9-0 that Moderna's mRNA flu vaccine's benefits outweigh its risks. A final approval decision is expected by Aug. 5.
Peers Comparison
Key metrics vs top competitors for Moderna, Inc. (MRNA)
| Company | Price | Market Cap | P/E Ratio | Rev Growth (1Y) | Net Margin | ROE | Div Yield |
|---|---|---|---|---|---|---|---|
| $79.77 | $31.64B | -10.99 | -39.23% | -145.16% | -28.87% | — | |
| $94.29 | $23.84B | -18.30 | 0.2% | -44.95% | -6.72% | — | |
| $9.46 | $1.56B | 3.72 | 64.69% | -14.73% | — | — | |
| $4.66 | $1.05B | 6.47 | 895.54% | 37.93% | 33.02% | — | |
| $24.07 | $136.92B | 17.70 | -1.65% | 11.83% | 8.34% | — | |
| $267.24 | $643.31B | 24.23 | 6.05% | 21.83% | 26.26% | — |
Compare MRNA vs Peers
Moderna, Inc. (MRNA) vs competitors — business, growth, and fundamentals comparison against the closest industry rivals.
MRNA SEC Filings & Documents
Moderna, Inc. (MRNA) SEC filings — annual & quarterly reports (10-K, 10-Q)
8-K Announcements
6Material company update
Mar 5, 2026·SEC
Material company update
Feb 13, 2026·SEC
Material company update
Feb 11, 2026·SEC
10-K Annual Reports
210-Q Quarterly Reports
6Get notified when MRNA posts new earnings or crosses analyst targets
Free. No account needed. Unsubscribe any time.
MRNA Frequently Asked Questions
Moderna, Inc. (MRNA) stock FAQ — growth, dividends, profitability & financials explained
Growth & Financials
What is Moderna, Inc.'s revenue?
Moderna, Inc. (MRNA) reported $2.23B in revenue for fiscal year 2025. This represents a 1953% increase from $108.4M in 2016.
How fast is Moderna, Inc. growing?
Moderna, Inc. (MRNA) saw revenue decline by 39.2% over the past year.
Is MRNA profitable?
Moderna, Inc. (MRNA) reported a net loss of $3.19B for fiscal year 2025.
Dividend & Returns
What is MRNA's return on equity?
Moderna, Inc. (MRNA) has a return on equity (ROE) of -28.9%. Negative ROE indicates the company is unprofitable.
What is Moderna, Inc.'s free cash flow?
Moderna, Inc. (MRNA) had negative free cash flow of $1.58B in fiscal year 2025, likely due to heavy capital investments.